Please ensure Javascript is enabled for purposes of website accessibility

Avanir Pharmaceuticals' Revenue Soars 62% on Strong Nuedexta Sales

By Sean Williams - Feb 5, 2014 at 5:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Avanir's loss shrinks as higher sales of PBA drug Nuedexta counter a rise in R&D and marketing costs.

Avanir Pharmaceuticals (NASDAQ: AVNR), a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported strong product sales growth in its first-quarter earnings results after the bell today.

For the quarter, Avanir reports that Nuedexta, a treatment for pseudobulbar affect, a neurological condition characterized by involuntary and sudden episodes of laughing and/or crying, saw revenue increase 15% from the sequential fourth quarter to $23.3 million (in net sales). Total net revenue expanded 62% to $26.7 million from the year-ago period. The remainder of Avanir's revenue was derived from co-promotion revenue with Merck (MRK -0.94%) for type 2 diabetes medication Januvia and from royalty revenue from the sale of Abreva.

Total operating expenses widened during the quarter to $36.7 million from $27.6 million in the previous year as selling and marketing expenses rose 29% and research and development costs jumped 43%.

Despite higher expenses, Avanir's net loss actually decreased during the quarter to $10.9 million, or $0.07 per share, from $12.1 million, or $0.09, in the year-ago period. Net cash used during the quarter was $9.8 million, with the company ending 2013 with $46.5 million in cash equivalents and investments in securities.

Although Avanir didn't provide any financial guidance for the remainder of fiscal 2014, it did promote specific quarter highlights, including the new drug application with the Food and Drug Administration for inhaled migraine medication AVP-825, and announced the enrollment of the first patient in a phase 2 proof-of-concept study of AVP-923 for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.75 (-0.94%) $0.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.